

Research Ethics Committee Reference Number	Name of Trial	Target number of patients	Date Agreed to recruit target number of patients
10/H0721/66	UBIOPRED: Unbiased BIOmarkers for the Prediction of Respiratory Disease Outcomes. Assessment of adults with severe asthma	87	30/04/2014
10/H0806/82	International Study of Incident Cancer (ISICA) - Breast Cancer and Diabetes	10	31/12/2011
11/H1003/90	A Sideguard Coronary Sidebranch Registry: A post market registry to observe the clinical outcomes of the Bare Metal Sideguard? Coronary Sidebranch stent in de novo Bifurcation Lesions of Native Coronary Arteries	10	04/09/2014
11/WA/0142	A Placebo-controlled, Double-blind, Randomised, Parallel-group, Long-term Phase III Trial Assessing the Safety and Efficacy of 50 mg and 100mg/day of eprotrirome in Patients with Heterozygous Familial Hypercholesterolaemia who are on Optimal Standard of Care	50	20/02/2014
11/NS/0020	Efficacy of ranolazine in patients with coronary artery disease (CAD)	12	28/12/2012
10/H0402/38	A randomised, double-blind, placebo-controlled, parallel-group, multicentre study to evaluate cardiovascular outcomes during treatment with lixisenatide in type 2 diabetic patients after an Acute Coronary Syndrome	6	03/04/2014

08/H1010/26	Open label study of Isavuconazole in the treatment of patients with Aspergillosis and Renal Impairment or of patients with Invasive Fungal Disease caused by rare molds, yeasts or dimorphic fungi (WSA-CS-003).	2	31/10/2013
12/NW/0006	A phase III, double blind, randomised study to evaluate safety and efficacy of BAL8557 versus Voriconazole for primary treatment of Invasive Fungal Disease caused by 2Aspergillus species or other filamentous fungi (WSA-CS-004).	2	01/04/2013
11/LO/2025	The Impact of Omalizumab Treatment in UK Clinical Practice (APEX II study)	20	26/07/2013
12/EM/0242	A randomised, double-blind, parallel group, dose-ranging study to evaluate the efficacy and safety of three different totally daily doses of fluticasone propionate inhaled from a new dry powder inhaler in subjects with severe persistent asthma requiring or	11	01/11/2013
11/NW/0690	Bardoxolone Methyl Evaluation in Patients with Chronic Kidney Disease and Type 2 Diabetes: The Occurrence of Renal Events (BEACON)	8	09/01/2014
12/SC/0469	Odyssey	5	01/07/2014
11/NW/0201	Simultaneous development of a questionnaire for use as an endpoint in clinical research in 3 languages: Evaluation of gas-related symptoms and their associated discomfort in the general population and in patients with Irritable Bowel Syndrome.	3	31/07/2012

12/WM/0194	A randomised, double-blind, placebo-controlled, phase 3 study to evaluate efficacy, safety and tolerability of JNJ-27018966 in the treatment of patients with diarrhea-predominant irritable bowel syndrome (IBS-D)	7	15/12/2013
12/NW/0145	A prospective, observational study in Europe to evaluate the direct and indirect economic burden of moderate to severe Irritable Bowel Syndrome with Constipation (IBIS-C Study)	20	25/11/2013
08/H0711/45	A multicentre, randomised, phase III trial of platinum-based chemotherapy versus non-platinum chemotherapy, after ERCC1 stratification in patients with advanced/metastatic non-small cell lung cancer	45	01/08/2016
11/LO/0054	NGR015: Randomized double-blind phase III study of NGR-hTNF plus best investigator's choice (BIC) versus placebo plus BIC in previously treated patients with advanced malignant pleural mesothelioma	12	01/08/2016
12/NW/0002	A Randomized, Open-label, Multicenter, Phase 3 Study to Compare the Efficacy and Safety of Eribulin with Treatment of Physician's Choice in Subjects with Advanced Non-Small Cell Lung Cancer (Elevate)	15	01/05/2016

12/NW/0431	A multi-centre, open-label, adaptive, randomised study of Palifosfamide-tris, a novel DNA Crosslinker, in combination with Carboplatin and Etoposide (PaCE) chemotherapy versus Carboplatin and Etoposide (CE) alone in chemotherapy naïve patients with extensi	15	01/09/2015
12/WM/0159	A randomised, phase 2, multi-centre, double-blind, placebo controlled study evaluating the efficacy and safety of MetMab in combination with either Bevacizumab + Platinum + Paclitaxel or Pemetrexed + Platinum as first-line treatment in patients with stage	4	31/10/2013
12/EE/0371	A multi-centre, randomised, active-controlled efficacy and safety study comparing extended duration Betrixaban with standard of care Enoxaparin for the prevention of venous thromboembolism in acute medically ill patients.	20	01/11/2014
12/NE/0181	A phase 3, randomised, single-blind, controlled trial of topical fibrocaps in intraoperative surgical haemostasis	60	30/04/2013
12/EM/0284	A multi-centre, open-label, long-term safety study of mepolizumab in asthmatic subjects who participated in the MEA112997 trial.	2	21/04/2016
12/WN/0341	A double-blind, randomised, placebo-controlled, multicentre study assessing the impact of additional LDL-cholesterol reduction on major cardiovascular events when AMG 145 is used in combination with statin therapy in patients with clinically evident cardio	22	08/04/2018

12/NW/0054	A randomised, double-blind, placebo-controlled crossover study to assess the efficacy of a single dose of 100mg of VRP700 by inhalation in reducing the frequency and severity of cough in adult patients with Idiopathic Pulmonary Fibrosis	20	30/09/2013
11/SC/0372	A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Evaluate the Safety and Efficacy of CCX140-B in Diabetic Nephropathy	5	05/04/2014
13/SC/0312	Screening for Advanced Heart Failure Treatment (SEE - HF)	25	04/07/2014
13/NI/0044	A study to measure Serum Periostin, asthma-related biomarkers and response to Prednisolone in adult and adolescent patients with severe oral corticosteroid-dependent asthma.	9	31/03/2014
13/NW/0215	A double blind, randomized, placebo controlled phase II study to assess the efficacy of recPRAME +AS15 Antigen-Specific Cancer Immunotherapeutic as adjuvant therapy in patients with resected PRAME-positive, Non-Small Cell Lung Cancer (PEARL-PRAME)	4	01/08/2020
13/LO/0501	A Phase 2, randomized, dose-ranging study to assess the safety and anti-cytomegalovirus (CMV) activity of Maribavir versus Valganciclovir for the treatment of CMV infections in transplant recipients who do not have cmv organ disease. Maribavir Study.	12	10/06/2014

Trial Status	Target met within the agreed time
Open	N/A
Closed - Follow Up Complete	Y
Open	N/A
Withdrawn	N/A
Open	N/A
Closed - In Follow Up	N/A

Open	N
Open	N
Open	N/A
Open	N/A
Withdrawn	N/A
Open	N/A
Closed - In Follow Up	Y

Open	N/A
Open	N/A
Open	N/A
Open	N/A
Open	N/A

Open	N/A
Open	N/A
Open	N/A
Open	N/A
Open	N/A
Open	N/A